Last reviewed · How we verify
Pf-04171327 (pf-04171327)
PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM).
PF-04171327, a nonsteroidal selective glucocorticoid receptor modulator by Pfizer, holds a unique market position with 97 approved indications, though it has not yet reached the clinical trial phase. Its competitive advantage lies in its steroid-like efficacy without the severe side effects associated with full glucocorticoid receptor agonists like Prednisolone and Prednisone. A key risk is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its broader application and market accessibility. The pipeline outlook remains promising with the development of PF-00251802, a selective high-affinity partial agonist of the glucocorticoid receptor and a prodrug of PF-04171327, potentially enhancing its therapeutic profile.
At a glance
| Generic name | pf-04171327 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Selective glucocorticoid receptor modulator (SGRM) |
| Target | Glucocorticoid receptor |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
PF-04171327 is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM). This means it works by modulating the glucocorticoid receptor, which is a protein that plays a crucial role in regulating inflammation and immune responses. By selectively modulating this receptor, PF-04171327 can provide a therapeutic effect without the side effects associated with traditional steroids.
Approved indications
- Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma after at least 2 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 3 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 4 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 5 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 6 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 7 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 8 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 9 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 10 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 11 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 12 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 13 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 14 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 15 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 16 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 17 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 18 prior lines of therapy
- Relapsed or Refractory Multiple Myeloma after at least 19 prior lines of therapy
Common side effects
- Upper respiratory tract infection
- Fatigue
- Nasopharyngitis
- Pharyngitis
- Viral infection
- Alanine aminotransferase increased
- Eosinophilia
- Neutropenia
- Visual impairment
- Abdominal pain upper
- Diarrhoea
- Vomiting
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- CYP2C8 inhibitors
- CYP2C8 inducers
- CYP2C19 inhibitors
- CYP2C19 inducers
- CYP2D6 inhibitors
- CYP2D6 inducers
- CYP1A2 inhibitors
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pf-04171327 CI brief — competitive landscape report
- Pf-04171327 updates RSS · CI watch RSS
- Pfizer portfolio CI